853297-06-0

Basic information

• Product Name: Benzenamine, 4-[[4-(1-methylethyl)-1-piperazinyl]methyl]-3-(trifluoromethyl)-
• Synonyms: 4-(4-isopropylpiperazin-1-ylmethyl)-3-trifluoromethyl-aniline
• CAS NO: 853297-06-0
• Molecular Formula: C15H22F3N3
• Molecular Weight: 301.35000
• Mol File: 853297-06-0.mol
• Article Data: 5

Chemical Properties

• Melting Point: 117 - 119 °C
• CAS DataBase Reference: Benzenamine, 4-[[4-(1-methylethyl)-1-piperazinyl]methyl]-3-(trifluoromethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenamine, 4-[[4-(1-methylethyl)-1-piperazinyl]methyl]-3-(trifluoromethyl)-(853297-06-0)
• EPA Substance Registry System: Benzenamine, 4-[[4-(1-methylethyl)-1-piperazinyl]methyl]-3-(trifluoromethyl)-(853297-06-0)

Safety Data

• Hazardous Substances Data: 853297-06-0(Hazardous Substances Data)

Upstream product

• 853297-07-1 2,2,2-trifluoro-N-[4-(4-isopropyl-piperazin-1-ylmethyl)-3-trifluoromethyl-phenyl]-acetamide 
• 350-96-9 2,2,2-trifluoro-N-(4-methylphenyl)acetamide 

Downstream Products

• 853298-47-2 N-[4-(2-methylamino-pyrimidin-4-yloxy)-phenyl]-N'-[4-(4-isopropylpiperazin-1-ylmethyl)-3-trifluoromethyl-phenyl]-urea 
• 853298-45-0 N-[4-(2-amino-pyrimidin-4-yloxy)-phenyl]-N'-[4-(4-isopropylpiperazin-1-ylmethyl)-3-trifluoromethyl-phenyl]-urea 
• 853297-05-9 N-[4-(6-chloro-pyrimidin-4-yloxy)-phenyl]-N'-[4-(4-isopropylpiperazin-1-ylmethyl)-3-trifluoromethyl-phenyl]-urea 
• 1232836-36-0 C₂₃H₂₇F₃IN₃O 
• 853297-08-2 N-[4-(6-methylamino-pyrimidin-4-yloxy)-phenyl]-N'-[4-(4-isopropylpiperazin-1-ylmethyl)-3-trifluoromethyl-phenyl]-urea 

Relevant articles and documents

ISOQUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES

The present invention discloses compounds according to Formula (I) wherein R1, R2, R3, L1, L2, and L3 are as defined herein. The present invention relates to compounds inhibiting discoidin domain receptors (DDRs), methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of fibrotic diseases, inflammatory diseases, respiratory diseases, autoimmune diseases, metabolic diseases, cardiovascular diseases, and/or proliferative diseases by administering a compound of the invention.

SUBSTITUTED PYRIMIDINYL AND PYRIDINYL-PYRROLOPYRIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS

The present invention relates to substituted pyrimidinyl- and pyridinylpyrrolopyridinone compounds which modulate the activity of protein kinases and are therefore useful in treating diseases caused by dysregulated protein kinase activity, in particular RET family kinases. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing pharmaceutical compositions containing these compounds.

DIARYL UREA DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES

The invention relates to the use of diaryl urea derivatives for the manufacture of pharmaceutical compositions for the treatment of RET dependent disorders, especially RET dependent tumor diseases. The invention further relates to novel N-[4-(pyrimidin-4-yloxy)-phenyl]-N’-phenyl-urea derivatives and their use in the treatment of the animal or human body, especially in the treatment of a protein kinase dependent disease, to pharmaceutical compositions comprising such novel N-[4-pyrimidin-4-yloxy)-phenyl]-N’-phenyl-urea derivatives and to the use of such novel N-[4-(pyrimidin-4-yloxy)-phenyl]-N’-phenyl-urea derivatives for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as tumour diseases.